Takeda Invests US$764 million for Plasma-Derived Manufacturing Facility in Japan
Introduction:
Takeda, a global pharmaceutical and biotechnology leader, is investing US$764 million to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan.
Features:
The new facility is the largest investment Takeda has ever made to expand its manufacturing capabilities in Japan.
The facility will be constructed in accordance with the highest global manufacturing standards, utilizing cutting-edge digital and automation technologies.
It will be a fully integrated plant with the ability to disassemble, fractionate, purify, fill, and finish products in addition to having a cold storage facility.
The design will be environmentally friendly, to support Takeda reach net-zero greenhouse gas emissions from operations, including scopes 1 and 2, before 2035.
Daily operations at Takeda's current Narita plasma manufacturing facility will continue through at least the end of the decade, with ongoing maintenance-related investments.
The new, state-of-the-art, which should be operational by around 2030, will be the biggest of its kind in the country.
The new facility nearly doubles the capacity of Takeda's present plasma manufacturing facility in Narita, Japan, and will allow the company to sustainably serve more patients in that country while also expanding the capacity of its global manufacturing network.
Specifications:
Name | Takeda |
Budget | US$764 million |
Type | New Construction |
Year | 2030 |
